Advertisement

Molecules and Cells

, Volume 36, Issue 4, pp 340–346 | Cite as

4-methoxychalcone enhances cisplatin-induced oxidative stress and cytotoxicity by inhibiting the Nrf2/ARE-mediated defense mechanism in A549 lung cancer cells

  • Juhee Lim
  • Sung Ho Lee
  • Sera Cho
  • Ik-Soo Lee
  • Bok Yun Kang
  • Hyun Jin ChoiEmail author
Research Article

Abstract

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcriptional regulator for the protection of cells against oxidative and xenobiotic stresses. Recent studies have demonstrated that high constitutive expression of Nrf2 is observed in many types of cancer cells showing resistance to anti-cancer drugs, suggesting that the suppression of overexpressed Nrf2 could be an attractive therapeutic strategy to overcome cancer drug resistance. In the present study, we aimed to find small molecule compounds that enhance the sensitivity of tumor cells to cisplatin induced cytotoxicity by suppressing Nrf2-mediated defense mechanism. A549 lung cancer cells were shown to be more resistant to the anti-cancer drug cisplatin than HEK293 cells, with higher Nrf2 signaling activity; constitutively high amounts of Nrf2-downstream target proteins were observed in A549 cells. Among the three chalcone derivatives 4-methoxy-chalcone (4-MC), hesperidin methylchalcone, and neohesperidin dihydrochalcone, 4-MC was found to suppress transcriptional activity of Nrf2 in A549 cells but to activate it in HEK293 cells. 4-MC was also shown to down-regulate expression of Nrf2 and the downstream phase II detoxifying enzyme NQO1 in A549 cells. The PI3K/Akt pathway was found to be involved in the 4-MC-induced inhibition of Nrf2/ARE activity in A549 cells. This inhibition of Nrf2 signaling results in the accelerated generation of reactive oxygen species and exacerbation of cytotoxicity in cisplatin-treated A549 cells. Taken together, these results suggest that the small molecule compound 4-MC could be used to enhance the sensitivity of tumor cells to the therapeutic effect of cisplatin through the regulation of Nrf2/ARE signaling.

Keywords

4-methoxychalcone A549 chemosensitivity cisplatin Nrf2 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alessi, D.R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., and Hemmings, B.A. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15, 6541–6551.PubMedGoogle Scholar
  2. Casares, C., Ramirez-Camacho, R., Trinidad, A., Roldan, A., Jorge, E., and Garcia-Berrocal, J.R. (2012). Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur. Arch. Otorhinolaryngol. 269, 2455–2459.PubMedCrossRefGoogle Scholar
  3. dos Santos, N.A., Carvalho Rodrigues, M.A., Martins, N.M., and dos Santos, A.C. (2012). Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch. Toxicol. 86, 1233–1250.PubMedCrossRefGoogle Scholar
  4. Feng, J., Zhang, P., Chen, X., and He, G. (2011). PI3K and ERK/Nrf2 pathways are involved in oleanolic acid-induced heme oxygenase-1 expression in rat vascular smooth muscle cells. J. Cell. Biochem. 112, 1524–1531.PubMedCrossRefGoogle Scholar
  5. Giudice, A., Arra, C., and Turco, M.C. (2010). Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. Methods Mol. Biol. 647, 37–74.PubMedCrossRefGoogle Scholar
  6. Hayes, J.D., McMahon, M., Chowdhry, S., and Dinkova-Kostova, A.T. (2010). Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox. Signal. 13, 1713–1748.PubMedCrossRefGoogle Scholar
  7. Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., et al. (2009). Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res. 15, 3423–3432.PubMedCrossRefGoogle Scholar
  8. Jaiswal, A.K. (2004). Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med. 36, 1199–1207.PubMedCrossRefGoogle Scholar
  9. Kachadourian, R., Day, B.J., Pugazhenti, S., Franklin, C.C., Genoux-Bastide, E., Mahaffey, G., Gauthier, C., Di Pietro, A., and Boumendjel, A. (2012). A synthetic chalcone as a potent inducer of glutathione biosynthesis. J. Med. Chem. 55, 1382–1388.PubMedCrossRefGoogle Scholar
  10. Kaspar, J.W., Niture, S.K., and Jaiswal, A.K. (2009). Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med. 47, 1304–1309.PubMedCrossRefGoogle Scholar
  11. Kensler, T.W., and Wakabayashi, N. (2010). Nrf2: friend or foe for chemoprevention?. Carcinogenesis 31, 90–99.PubMedCrossRefGoogle Scholar
  12. Kim, H.R., Kim, S., Kim, E.J., Park, J.H., Yang, S.H., Jeong, E.T., Park, C., Youn, M.J., So, H.S., and Park, R. (2008). Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 60, 47–56.PubMedCrossRefGoogle Scholar
  13. Kim, T.H., Seo, W.D., Ryu, H.W., Seo, H.R., Jin, Y.B., Lee, M., Ji, Y.H., Park, K.H., and Lee, Y.S. (2010). Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production. Chem. Biol. Interact. 188, 111–118.PubMedCrossRefGoogle Scholar
  14. Kweon, M.H., Adhami, V.M., Lee, J.S., and Mukhtar, H. (2006). Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J. Biol. Chem. 281, 33761–33772.PubMedCrossRefGoogle Scholar
  15. Lau, A., Villeneuve, N.F., Sun, Z., Wong, P.K., and Zhang, D.D. (2008). Dual roles of Nrf2 in cancer. Pharmacol. Res. 58, 262–270.PubMedCrossRefGoogle Scholar
  16. Lee, I.S., Lim, J., Gal, J., Kang, J.C., Kim, H.J., Kang, B.Y., and Choi, H.J. (2011). Anti-inflammatory activity of xanthohumol involves heme oxygenase-1 induction via NRF2-ARE signaling in microglial BV2 cells. Neurochem. Int. 58, 153–160.PubMedCrossRefGoogle Scholar
  17. Lee, Y.H., Jeon, S.H., Kim, S.H., Kim, C., Lee, S.J., Koh, D., Lim, Y., Ha, K., and Shin, S.Y. (2012a). A new synthetic chalcone derivative, 2-hydroxy-3′,5,5′-trimethoxychalcone (DK-139), suppresses the Toll-like receptor 4-mediated inflammatory response through inhibition of the Akt/NF-kappaB pathway in BV2 microglial cells. Exp. Mol. Med. 44, 369–377.PubMedCrossRefGoogle Scholar
  18. Lee, C.K., Park, K.K., Chung, A.S., and Chung, W.Y. (2012b). Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem. Toxicol. 50, 2565–2574.PubMedCrossRefGoogle Scholar
  19. Liao, Y., Lu, X., Lu, C., Li, G., Jin, Y., and Tang, H. (2008). Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacol. Res. 57, 125–131.PubMedCrossRefGoogle Scholar
  20. Lim, J.H., Kim, K.M., Kim, S.W., Hwang, O., and Choi, H.J. (2008). Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacol. Res. 57, 325–331.PubMedCrossRefGoogle Scholar
  21. Ma, Y., Wu, X., Li, X., Fu, J., Shen, J., and Wang, H. (2012). Corticosterone regulates the expression of neuropeptide Y and reelin in MLO-Y4 cells. Mol. Cells 33, 611–616.PubMedCrossRefGoogle Scholar
  22. Papaiahgari, S., Zhang, Q., Kleeberger, S.R., Cho, H.Y., and Reddy, S.P. (2006). Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells. Antioxid. Redox. Signal. 8, 43–52.PubMedCrossRefGoogle Scholar
  23. Park, S.J., Song, H.Y., and Youn, H.S. (2009). Suppression of the TRIF-dependent signaling pathway of toll-like receptors by isoliquiritigenin in RAW264.7 macrophages. Mol. Cells 28, 365–368.CrossRefGoogle Scholar
  24. Rao, Y.K., Kao, T.Y., Ko, J.L., and Tzeng, Y.M. (2010). Chalcone HTMC causes in vitro selective cytotoxicity, cell-cycle G1 phase arrest through p53-dependent pathway in human lung adenocarcinoma A549 cells, and in vivo tumor growth suppression. Bioorg. Med. Chem. Lett. 20, 6508–6512.PubMedCrossRefGoogle Scholar
  25. Ren, D., Villeneuve, N.F., Jiang, T., Wu, T., Lau, A., Toppin, H.A., and Zhang, D.D. (2011). Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. USA 108, 1433–1438.PubMedCrossRefGoogle Scholar
  26. Singh, A., Bodas, M., Wakabayashi, N., Bunz, F., and Biswal, S. (2010). Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid. Redox. Signal. 13, 1627–1637.PubMedCrossRefGoogle Scholar
  27. Sporn, M.B., and Liby, K.T. (2012). NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12, 564–571.PubMedCrossRefGoogle Scholar
  28. Szliszka, E., Czuba, Z.P., Mazur, B., Paradysz, A., and Krol, W. (2010). Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells. Molecules 15, 5336–5353.PubMedCrossRefGoogle Scholar
  29. Vogel, S., Barbic, M., Jurgenliemk, G., and Heilmann, J. (2010). Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect. Eur. J. Med. Chem. 45, 2206–2213.PubMedCrossRefGoogle Scholar
  30. Wang, X.J., Sun, Z., Villeneuve, N.F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G.T., et al. (2008). Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29, 1235–1243.PubMedCrossRefGoogle Scholar
  31. Yadav, V.R., Prasad, S., Sung, B., and Aggarwal, B.B. (2011). The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int. Immunopharmacol. 11, 295–309.PubMedCrossRefGoogle Scholar
  32. Zhang, D.D. (2010). The Nrf2-Keap1-ARE signaling pathway: the regulation and dual function of Nrf2 in cancer. Antioxid. Redox. Signal. 13, 1623–1626.PubMedCrossRefGoogle Scholar

Copyright information

© The Korean Society for Molecular and Cellular Biology and Springer Netherlands 2013

Authors and Affiliations

  • Juhee Lim
    • 1
  • Sung Ho Lee
    • 2
  • Sera Cho
    • 2
  • Ik-Soo Lee
    • 2
  • Bok Yun Kang
    • 2
  • Hyun Jin Choi
    • 1
    Email author
  1. 1.College of PharmacyCHA UniversitySeongnamKorea
  2. 2.College of Pharmacy and Research Institute of Drug DevelopmentChonnam National UniversityGwangjuKorea

Personalised recommendations